

Ret (phospho Tyr905) Polyclonal Antibody

Catalog No: YP1148

Reactivity: Human; Mouse; Rat

Applications: IHC;IF;ELISA

Target: Ret

Fields: >>Calcium signaling pathway;>>Pathways in cancer;>>Thyroid cancer;>>Non-

small cell lung cancer;>>Central carbon metabolism in cancer

Gene Name: RET

Protein Name: Proto-oncogene tyrosine-protein kinase receptor Ret

P07949

P35546

Human Gene Id: 5979

Human Swiss Prot

No:

Mouse Gene Id: 19713

Mouse Swiss Prot

No:

Immunogen: The antiserum was produced against synthesized peptide derived from human

Ret around the phosphorylation site of Tyr905. AA range:881-930

Specificity: Phospho-Ret (Y905) Polyclonal Antibody detects endogenous levels of Ret

protein only when phosphorylated at Y905.

Formulation : Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Source: Polyclonal, Rabbit, IgG

Dilution: IHC 1:100 - 1:300. IF 1:200 - 1:1000. ELISA: 1:5000. Not yet tested in other

applications.

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-

chromatography using epitope-specific immunogen.



Concentration: 1 mg/ml

Storage Stability: -15°C to -25°C/1 year(Do not lower than -25°C)

Molecularweight: 124kD

Cell Pathway: Endocytosis; Pathways in cancer; Thyroid cancer;

Background : ret proto-oncogene(RET) Homo sapiens This gene, a member of the cadherin

superfamily, encodes one of the receptor tyrosine kinases, which are cell-surface molecules that transduce signals for cell growth and differentiation. This gene plays a crucial role in neural crest development, and it can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. Mutations in this gene are associated with the disorders multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, Hirschsprung disease, and medullary thyroid carcinoma. Two transcript variants encoding different isoforms have been found for this gene. Additional transcript variants have been described but their

biological validity has not been confirmed. [provided by RefSeq, Jul 2008],

Function : catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine

phosphate., disease: Chromosomal aberrations involving RET are a cause of thyroid papillary carcinoma (PACT) [MIM:188550]. Inversion inv(10)(q11.2;q21) generates the RET/CCDC6 (PTC1) oncogene; inversion inv(10)(q11.2;q11.2) generates the RET/NCOA4 (PTC3) oncogene; translocation t(10;14)(q11;q32) with GOLGA5 generates the RET/GOLGA5 (PTC5) oncogene; translocation t(8;10)(p21.3;q11.2) with PCM1 generates the PCM1/RET fusion; translocation

t(6;10)(p21.3;q11.2) with RFP generates the Delta RFP/RET oncogene; translocation t(1;10)(p13;q11) with TRIM33 generates the TRIM33/RET (PTC7) oncogene; translocation t(7;10)(q32;q11) with TIF1 generates the TIF1/RET (PTC6) oncogene. The PTC5 oncogene has been found in 2 cases of PACT in children exposed to radioactive fallout after Chernobyl.,disease:Defects in RET

are a cause o

Subcellular

Cell membrane ; Single-pass type I membrane protein . Endosome membrane ;

Single-pass type I membrane protein . Predominantly located on the plasma

membrane. In the presence of SORL1 and GFRA1, directed to endosomes. .

Expression: Blood, Brain, Fibroblast, Leukocyte, Neural crest, Peripheral blood

leukocyte, Thyroid papillary

Products Images